Johnson & Johnson (XTER:JNJ) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:JNJ Johnson & Johnson XTER:JNJ
86 GF Score
Price €222.55
GF Value €170.16
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson SpecialCharges?

Special Charges only applies to banks.

XTER:JNJ
86GF Score
Johnson & Johnson XTER:JNJ
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (XTER:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of €222.55 is trading 30.8% above its estimated GF Value™ of €170.16. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for XTER:JNJ:

  • SpecialCharges:
  • GF Value™: €170.16 vs. price of €222.55 (30.8% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the XTER:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
86GF Score

Get the complete analysis for XTER:JNJ

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€222.55
Price
€170.16
GF Value